Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00592332 |
Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.
Condition | Intervention |
---|---|
Type 1 Diabetes |
Drug: Alprazolam Other: control group |
Study Type: | Interventional |
Study Design: | Randomized, Single Blind (Subject), Active Control, Crossover Assignment |
Official Title: | Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2 |
Estimated Enrollment: | 56 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
2: Experimental
Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
|
Drug: Alprazolam
1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
|
1: Experimental
Hyperinsulinemic glucose clamp in group with no drug.
|
Other: control group
control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
|
Due to the fundamental importance of glucose as a cerebral fuel, a complex and redundant counterregulatory response to hypoglycemia exists in man. Some studies have shown that prior activation of GABA(A) receptors may result in blunting of counterregulatory responses during next day hypoglycemia.
The Specific Aim is to determine if repeated activation of GABA(A) receptors using Alprazolam will result in blunting of neuroendocrine, ANS and metabolic counterregulatory mechanisms during next day hypoglycemia in T1DM and healthy man.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Tennessee | |
Vanderbilt University | |
Nashville, Tennessee, United States, 37232 |
Principal Investigator: | Stephen N Davis, MD | Vanderbilt University |
Responsible Party: | Vanderbilt University ( Stephen N. Davis ) |
Study ID Numbers: | IRB#040908-HAAF-T1DM-Q2, DK69803 |
Study First Received: | January 1, 2008 |
Last Updated: | December 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00592332 |
Health Authority: | United States: Institutional Review Board |
Alprazolam Autoimmune Diseases Metabolic Diseases Diabetes Mellitus, Type 1 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Hypoglycemia |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Immune System Diseases GABA Modulators Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Pharmacologic Actions Therapeutic Uses Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Central Nervous System Agents |